FDA notifications. FDA issues public health advisory about ESAs.
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000009:adverse effects
D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D015215:Zidovudine; D000068817:Epoetin Alfa